MIRM SEC Filing News — Mirum Pharmaceuticals, Inc.

Latest SEC filings for Mirum Pharmaceuticals, Inc. (MIRM) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-14.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercializat…
Sector: Healthcare Industry: Biotechnology Market Cap: $5.3B
20
Total Filings
0
Bullish Classifications
7
Bearish Classifications
9
Insider Transactions
4
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for MIRM currently lean bearish. Of the 20 filing records displayed, 7 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
MIRM Filing Activity Snapshot 2026-08-05 — 2026-10-14
Insider Transactions (Form 4)
0 buys vs 7 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$4.00M
Howe Jolanda (SVP, GLOBAL CONTROLLER) · 2026-08-19
40,000 shares · Form 4
Form 144 Notices
6
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Mirum Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 7 open-market sale, 1 compensation award and 1 option exercise. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×7
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×1
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Option exercise ×1
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Compensation award Tax / Compensation Filing 2026-10-14

MIRM insider Form 4 filed for equity award, exercise, or tax withholding

Myers Robert Paul (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Employee Stock Option (right to buy) 40,000 — —
A Compensation award derivative · Restricted Stock Units 25,000 — —
Filing: Form 4 (Insider Transaction) Insider: Myers Robert Paul (Chief Medical Officer)
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-10-06

MIRM insider Form 4 filed for equity award, exercise, or tax withholding

Peetz Christopher (Director, CHIEF EXECUTIVE OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 5,305 $19.19 $101.8K
M Option exercise 6,892 $15.87 $109.4K
M Option exercise derivative · Employee Stock Option (right to buy) 5,305 — —
M Option exercise derivative · Employee Stock Option (right to buy) 6,892 — —
Filing: Form 4 (Insider Transaction) Insider: Peetz Christopher (Director, CHIEF EXECUTIVE OFFICER) Shares: 12,197
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-15

MIRM insider BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) sold 9,943 shares (~$978.1K)

BJERKHOLT ERIC, listed as CHIEF FINANCIAL OFFICER at Mirum Pharmaceuticals, Inc., reported an open-market sale of 9,943 MIRM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 18,333 — —
S Open-market sale 9,943 $98.37 $978.1K
M Option exercise derivative · Restricted Stock Units 18,333 — —
Filing: Form 4 (Insider Transaction) Insider: BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) Shares: 9,943 Est. Value: $978.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-03

MIRM insider Howe Jolanda (SVP, GLOBAL CONTROLLER) sold 658 shares (~$65.8K)

Howe Jolanda, listed as SVP, GLOBAL CONTROLLER at Mirum Pharmaceuticals, Inc., reported an open-market sale of 658 MIRM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 658 $100.00 $65.8K
Filing: Form 4 (Insider Transaction) Insider: Howe Jolanda (SVP, GLOBAL CONTROLLER) Shares: 658 Est. Value: $65.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-03

MIRM insider Peetz Christopher (Director, CHIEF EXECUTIVE OFFICER) sold 30,000 shares (~$2.96M)

Peetz Christopher, listed as Director, CHIEF EXECUTIVE OFFICER at Mirum Pharmaceuticals, Inc., reported an open-market sale of 30,000 MIRM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 30,000 $2.94 $88.1K
S Open-market sale 8,312 $98.08 $815.2K
S Open-market sale 21,688 $98.91 $2.15M
M Option exercise derivative · Employee Stock Option (right to buy) 30,000 — —
Filing: Form 4 (Insider Transaction) Insider: Peetz Christopher (Director, CHIEF EXECUTIVE OFFICER) Shares: 30,000 Est. Value: $2.96M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-19

MIRM insider Howe Jolanda (SVP, GLOBAL CONTROLLER) sold 40,000 shares (~$4.00M)

Howe Jolanda, listed as SVP, GLOBAL CONTROLLER at Mirum Pharmaceuticals, Inc., reported an open-market sale of 40,000 MIRM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 40,000 $6.27 $250.8K
S Open-market sale 40,000 $100.00 $4.00M
M Option exercise derivative · Employee Stock Option (right to buy) 40,000 — —
Filing: Form 4 (Insider Transaction) Insider: Howe Jolanda (SVP, GLOBAL CONTROLLER) Shares: 40,000 Est. Value: $4.00M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-12

MIRM insider BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) sold 6,001 shares (~$599.5K)

BJERKHOLT ERIC, listed as CHIEF FINANCIAL OFFICER at Mirum Pharmaceuticals, Inc., reported an open-market sale of 6,001 MIRM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 6,001 $99.90 $599.5K
Filing: Form 4 (Insider Transaction) Insider: BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) Shares: 6,001 Est. Value: $599.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-11

MIRM insider Peetz Christopher (Director, CHIEF EXECUTIVE OFFICER) sold 20,000 shares (~$1.98M)

Peetz Christopher, listed as Director, CHIEF EXECUTIVE OFFICER at Mirum Pharmaceuticals, Inc., reported an open-market sale of 20,000 MIRM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 20,000 $2.94 $58.7K
S Open-market sale 11,683 $98.51 $1.15M
S Open-market sale 6,017 $99.25 $597.2K
S Open-market sale 2,300 $100.14 $230.3K
M Option exercise derivative · Employee Stock Option (right to buy) 20,000 — —
Filing: Form 4 (Insider Transaction) Insider: Peetz Christopher (Director, CHIEF EXECUTIVE OFFICER) Shares: 20,000 Est. Value: $1.98M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-05

MIRM insider Howe Jolanda (SVP, GLOBAL CONTROLLER) sold 1,840 shares (~$193.7K)

Howe Jolanda, listed as SVP, GLOBAL CONTROLLER at Mirum Pharmaceuticals, Inc., reported an open-market sale of 1,840 MIRM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,840 $105.29 $193.7K
Filing: Form 4 (Insider Transaction) Insider: Howe Jolanda (SVP, GLOBAL CONTROLLER) Shares: 1,840 Est. Value: $193.7K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Mirum Pharmaceuticals, Inc. has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-15

MIRM Form 144 filed for proposed insider sale by ERIC BJERKHOLT (9,943 shares) ~$978.1K

ERIC BJERKHOLT filed a Form 144 with the SEC indicating intent to sell MIRM (Mirum Pharmaceuticals, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ERIC BJERKHOLT Shares: 9,943 Est. Value: $978.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-02

MIRM Form 144 filed for proposed insider sale by JOLANDA MARIE HOWE (658 shares) ~$65.8K

JOLANDA MARIE HOWE filed a Form 144 with the SEC indicating intent to sell MIRM (Mirum Pharmaceuticals, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JOLANDA MARIE HOWE Shares: 658 Est. Value: $65.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-01

MIRM Form 144 filed for proposed insider sale by CHRISTOPHER PEETZ (30,000 shares) ~$2.96M

CHRISTOPHER PEETZ filed a Form 144 with the SEC indicating intent to sell MIRM (Mirum Pharmaceuticals, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: CHRISTOPHER PEETZ Shares: 30,000 Est. Value: $2.96M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-18

MIRM Form 144 filed for proposed insider sale by JOLANDA MARIE HOWE (40,000 shares) ~$4.00M

JOLANDA MARIE HOWE filed a Form 144 with the SEC indicating intent to sell MIRM (Mirum Pharmaceuticals, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JOLANDA MARIE HOWE Shares: 40,000 Est. Value: $4.00M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-11

MIRM Form 144 filed for proposed insider sale by ERIC BJERKHOLT (6,001 shares) ~$599.5K

ERIC BJERKHOLT filed a Form 144 with the SEC indicating intent to sell MIRM (Mirum Pharmaceuticals, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ERIC BJERKHOLT Shares: 6,001 Est. Value: $599.5K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-10

MIRM Form 144 filed for proposed insider sale by CHRISTOPHER PEETZ (20,000 shares) ~$1.98M

CHRISTOPHER PEETZ filed a Form 144 with the SEC indicating intent to sell MIRM (Mirum Pharmaceuticals, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: CHRISTOPHER PEETZ Shares: 20,000 Est. Value: $1.98M
View on SEC EDGAR → Open Filing Document →
Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Mirum Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-13

MIRM filed 8-K — material company event

Mirum Pharmaceuticals, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-28

MIRM filed 8-K — material company event

Mirum Pharmaceuticals, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-08

MIRM filed 8-K — material company event

Mirum Pharmaceuticals, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-05

MIRM filed 8-K — material company event

Mirum Pharmaceuticals, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Mirum Pharmaceuticals, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

MIRM filed Quarterly Report (10-Q)

Mirum Pharmaceuticals, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Mirum Pharmaceuticals, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on MIRM. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — MIRM SEC Filings

More Tools for MIRM

MIRM Full Stock Analysis MIRM Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper MIRM analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the MIRM stock analysis page.

MIRM Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer